SymBio Pharmaceuticals - Self-commercialisation gains favour
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
59 Views
Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
150 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
73 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
68 Views
SymBio Pharmaceuticals - New formulations extend Treakisym patent life
SymBio has substantially increased the value of its Treakisym franchise through in-licensing novel bendamustine formulations from Eagle...
68 Views